Sevoflurane Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 1.15 Bn

Forecast Year, 2035

USD 2.02 Bn

CAGR, 2026 - 2035

5.80%

Report Coverage

Global

Sevoflurane Market Size and Forecast 2026 to 2035

The global sevoflurane market size accounted for USD 1.15 billion in 2025 and is predicted to increase from USD 1.22 billion in 2026 to approximately USD 2.02 billion by 2035, expanding at a CAGR of 5.80% from 2026 to 2035. Growing surgical volumes, increasing healthcare expenditure, expansion of ambulatory surgical centers, rising prevalence of chronic diseases requiring surgical intervention, and advancements in anesthesia delivery systems are driving market growth.

Key Takeaways

• North America led the sevoflurane market with a share of 36% in 2025.
• Asia-Pacific is expected to be the fastest-growing region with a CAGR of 7.5% in the forecasted duration.
• By product, the branded sevoflurane segment held a dominant position in the market with a share of 42% in 2025
• By product, the generic sevoflurane segment is expected to grow at the fastest CAGR of 7.6% in the market between 2026 and 2035.
• By formulation, the liquid sevoflurane segment accounted for a considerable revenue share of 82% in the market in 2025.
• By formulation, the stabilized sevoflurane segment is expected to grow with the highest CAGR of 7.8% in the market during the studied years.
• By application, the general surgery segment led the global market with a share of 32% in 2025.
• By application, the ambulatory surgery segment is expected to expand rapidly in the market with a CAGR of 7.5% in the coming years.
• By end user, the hospitals segment registered its dominance over the global sevoflurane market with a share of 68% in 2025.
• By end user, the ambulatory surgical centers segment is expected to witness the fastest growth in the market with a CAGR of 7.9% over the forecast period.
• By distribution channel, the direct tender sales segment led the global market with a share of 46% in 2025.
• By distribution channel, the online procurement platforms segment is expected to expand rapidly in the market with a CAGR of 8.8% in the coming years.

Market Overview

Sevoflurane is an ether-based inhalation general anesthetic known for its lower blood solubility. This characteristic leads to more predictable decannulation times and significantly improved postoperative outcomes. Additionally, sevoflurane exhibits minimal airway irritant effects, allowing for smoother induction, particularly when compared to halothane in pediatric patients. Furthermore, it poses a reduced risk of hepatic injury. These advantageous properties not only enhance their appeal over other anesthetic agents but also contribute to their growing presence in the market.

Impact of Artificial Intelligence on the Sevoflurane Market

Artificial intelligence (AI) has the potential to monitor states of anesthesia and greatly reduce inaccurate dosing of drugs and associated side effects. By training algorithms specifically on sevoflurane data, we can create models tailored to this anesthetic. Furthermore, machine learning may successfully classify expired sevoflurane concentrations in young infants when used with quantitative EEG (qEEG). The careful selection of EEG parameters and the identification of the most effective machine learning models will be vital for advancing EEG algorithms tailored for infants in the future.

Sevoflurane Market Trends

• Growing Preference in Pediatric Anaesthesia: Sevoflurane continues to be a preferred agent of anaesthesia for induction and maintenance of paediatric anaesthesia for its rapid induction and recovery characteristics, nonpungency and pleasant odour, and an acceptable cardiovascular profile.
• Rising Adoption of Inhalation Anesthesia: The increasing trend of inhalation anaesthesia has increased the use of sevoflurane because of its non-flammability, non-irritant nature, and rapid induction and emergence.
• Expanding Use in Outpatient Anesthesia: Sevoflurane appears to have several properties that make it an attractive alternative to currently available anaesthetics for outpatient anaesthesia, supported by its relatively low solubility and impressive lack of airway irritation.

Market Report Coverage and Key Metrics

Market Dynamics

Drivers

Rising Surgical Volumes and Growing Demand for Minimally Invasive Procedures

The demand for sevoflurane is being driven by a rise in inpatient and outpatient surgery, a fast-growing demand for minimally invasive medical procedures, and improving standards for surgical care supported by its low solubility, lack of airway irritation, and suitability for inhalation induction anaesthesia.

Restraint

Limited Production Base and Accessibility Challenges

The major restraint of the sevoflurane market is a limited number of players dealing with the sevoflurane production, which makes it less affordable as well as less accessible in remote areas. The presence of dominant players and difficult certification procedures restricts the establishment of regional players.

Opportunity

Expanding Research Activities and Rural Market Penetration

There are significant opportunities in sevoflurane research activities. There is a growing scientific interest in clinical trials for anesthetic procedures and adverse events as well as broader substance applications and unexploited potential for suppliers to increase availability in rural areas requiring proper anaesthesia.

Market Segmentation Analysis

Product Type Insights

The Branded Sevoflurane Segment Dominated the Market with 42% of Market Share in 2025

The branded sevoflurane segment dominated the sevoflurane market with a share of 42% in 2025, driven by its established clinical trust and consistent product quality. Moreover, it holds all the necessary regulatory approvals for use. Strong brand recognition, hospital preference, and long-term contracts with established healthcare platforms further support its dominance.

Sevoflurane Market Share, By Product Type, 2025-2035 (%)

The generic sevoflurane segment accounted for 35% of the market in 2025 and is expected to be the fastest growing, with a CAGR of 7.6% from 2026 to 2035. Growth is supported by its cost-effectiveness for middle and low-income populations, patent expiry benefits enabling equivalent formulations to the original drug, increasing adoption in developing countries, competitive pricing, and a hospital procurement focus in rural areas.

The high-purity sevoflurane segment captured 10% of the market share in 2025 and is expected to grow at a CAGR of 4.8% in the coming years, driven by stringent quality requirements for specialized surgeries. Rising demand from premium hospitals, a strong emphasis on patient safety, support for advanced and personalized surgical procedures, and adherence to compliance standards further fuel this segment's growth.

Formulation Insights

The Liquid Sevoflurane Segment Led the Market with 82% Share in 2025

The liquid sevoflurane segment led the sevoflurane market with a 82% share in 2025, driven by its standard market format and widespread availability. This formulation presents an effective and cost-efficient clinical alternative for certain patients, making it suitable for complex wound care. Additionally, its established clinical use, cost-effectiveness, and global acceptance contribute to its continued growth.

The stabilized sevoflurane segment captured 18% of the market share in 2025 and is expected to grow at the fastest CAGR of 7.8% during the forecast period. This growth is driven by its enhanced shelf life, product stability, and reduced risk of degradation. Furthermore, the quality assurance it offers and its suitability for premium applications further bolster its market potential.

Application Insights

The General Surgery Segment Held the Largest Market Share of 32% in 2025

The general surgery segment held the largest revenue share of 32% in the sevoflurane market in 2025, driven by high procedure volumes and broad clinical applicability. Moreover, rising surgical demand, increasing hospital admissions for general surgery, and a growing aging population further support its dominance.

Sevoflurane Market Share, By Application, 2025-2035 (%)

The cardiovascular surgery segment secured 15% of the market share in 2025 and is expected to grow at a CAGR of 5.5% in the coming years, owing to rising cardiac disorders, increasing adoption of minimally invasive surgical procedures, and ongoing surgical advancements. Additionally, growing demand for specialized anesthesia, a larger elderly population, higher healthcare spending, and wider insurance coverage all support this segment's growth.

The ambulatory surgery segment accounted for 12% of the market share in 2025 and is expected to grow at the highest CAGR of 7.5% during the forecast period, driven by the expansion of outpatient surgeries. An increase in same-day surgical procedures, faster recovery benefits, and cost efficiency are key growth contributors. Furthermore, the expansion of ambulatory surgical centers (ASCs) and the high level of patient convenience they provide further support segment growth.

End User Insights

The Hospitals Segment Dominated the Market with a 68% Share in 2025

The hospitals segment dominated the sevoflurane market with a 65% share in 2025, driven by the large volume of surgical procedures. In addition, hospitals offer critical care infrastructure, multidisciplinary teams, and specialized anesthesiologists. High-value procurement contracts, specialized departments, and strong patient inflow further reinforce their dominance.

The ambulatory surgical centers (ASCs) segment accounted for 18% of the market share in 2025 and is expected to expand rapidly with a CAGR of 7.9% in the coming years, driven by the expansion of day-care surgeries. ASCs offer cost-effective care for middle- to low-income populations and enable shorter hospital stays. Rising outpatient procedures and greater operational efficiency further support the growth of this segment.

The specialty clinics segment held 10% of the market share in 2025 and is expected to grow at a CAGR of 5.6% during the forecast period, supported by the increasing number of specialized surgical procedures. These clinics provide advanced care services and procedure-specific solutions. Additionally, higher patient convenience and strong clinical expertise are driving their adoption.

Distribution Channel Insights

The Direct Tender Sales Segment Led the Market With a 46% Share in 2025

The direct tender sales segment contributed the biggest sevoflurane market share of 46% in 2025, driven by government procurement processes and support for large-volume purchases. In addition, large hospital contracts and competitive pricing enable high-volume procurement and long-term agreements with healthcare associations, reinforcing this segment's dominance.

The pharmaceutical distributors segment accounted for 25% of the market share in 2025 and is expected to grow at a CAGR of 5.1% in the coming years. Growth is supported by broad market coverage and high supply chain efficiency. Moreover, a wide range of product availability, strong regional distribution networks, and efficient customer support further promote the adoption of this channel.

The online procurement platforms segment held 5% of the market share in 2025 and is expected to witness the fastest growth with a CAGR of 8.8% over the forecast period. This growth is driven by the rapid adoption of digital procurement solutions and enhanced supply chain transparency. In addition, procurement efficiency, expanding hospital digitization, and a strong focus on cost optimization are key factors supporting the growth of this segment.

Market Regional Analysis: North America, Europe, Asia-Pacific

U.S. Sevoflurane Market Size and Growth 2026 to 2035

The U.S. sevoflurane market size was evaluated at USD 310 million in 2025 and is projected to reach around USD 530 million by 2035, growing at a CAGR of 5.51% from 2026 to 2035.

Why Did North America Dominate the Sevoflurane Market?

North America held a major market share of 36% in 2025. Growth is driven by advanced healthcare infrastructure and rapid adoption of new formulations following market entry. Furthermore, high surgical volumes, along with favourable reimbursement and insurance coverage, support market expansion.

U.S. Market Analysis

The U.S. leads the North American market, supported by increasing R&D activities from several small and medium enterprises focused on enhancing medical and healthcare facilities. Moreover, rising product launches and regulatory approvals, as well as the presence of organizations such as the FDA and United Surgical Partners International, further support market growth.

Which Factors Drive the Sevoflurane Market in Asia-Pacific?

Asia-Pacific accounted for 24% of the market share in 2025 and is expected to experience the fastest growth with a CAGR of 7.5% during the predicted timeframe, driven by healthcare infrastructure expansion and the rising volume of inpatient and outpatient surgeries. A large population base, increasing healthcare expenditure, and improved patient access further promote regional market growth.

China Market Analysis

China is at the forefront of the Asia-Pacific market, driven by expanding healthcare infrastructure, the rising prevalence of surgical procedures, and strategic government initiatives aimed at achieving pharmaceutical self-sufficiency. In addition, a growing middle-class population is increasing demand for minimally invasive techniques.

How is Europe Growing in the Sevoflurane Market?

Europe held 28% of the market share in 2025 and is expected to grow at a CAGR of 5% from 2026 to 2035, supported by a strong hospital network and a growing elderly population. Furthermore, high-quality product usage and high procedural volumes promote market expansion. The region also benefits from universal healthcare coverage and well-established anesthesia protocols.

Germany Market Analysis

Germany is performing strongly in the European market, driven by increasing medical tourism and environmental standards that encourage low-flow anesthesia adoption. Excellence in medical training supports safe anesthetic administration, while domestic pharmaceutical manufacturing enhances supply reliability and supports market growth.

Will the Middle East and Africa Grow in the Sevoflurane Market?

The Middle East and Africa held 5% of the market share in 2025 and is expected to grow at a CAGR of 4.5% in the coming years. Growth is propelled by hospital modernization and government-led healthcare investments. Moreover, increasing surgical procedures and medical tourism are improving healthcare access and thereby supporting market expansion.

UAE Market Analysis

The UAE is experiencing notable market growth, supported by substantial investment in healthcare facilities. Key enterprises are localizing strategies to cater to specific regional needs. Increasing medical tourism, growing R&D activities, and the rising adoption of safe anesthesia practices further support market growth.

What are the Key Trends of the Sevoflurane Market in Latin America?

Latin America held 7% of the market share in 2025 and is expected to grow at a CAGR of 4.8% over the forecast period, supported by expanding healthcare facilities and rising surgical interventions. In addition, government-led healthcare investments, growing insurance coverage, and the expansion of private hospitals contribute to market development.

Brazil Market Analysis

Brazil is performing well in the Latin American market, driven by improved healthcare access, rising health awareness, and increasing adoption of minimally invasive therapies. Moreover, companies are focusing on establishing regional partnerships to enhance distribution and strengthen market presence.

Market Competitive Landscape: Leading Companies and Strategies

The sevoflurane market is highly consolidated, with key players producing generic sevoflurane that is uniquely packaged in aluminum containers to prevent chemical degradation. These companies have established significant trust within clinical settings and maintain a strong market presence in major hospitals.

One of the primary challenges in this market is the significant protection afforded by a few dominant players, making it difficult for smaller organizations to enter. Nevertheless, the company is actively pursuing international certifications to facilitate expansion into new markets. Additionally, government initiatives are supporting the development of the infrastructure necessary for large-scale local production and export of generic volatile anesthetics.

Sevoflurane Market Companies

• Baxter International
• AbbVie Inc. (Legacy Allergan Anesthesia Portfolio)
• Piramal Pharma Limited
• Halocarbon Life Sciences
• Lunan Pharmaceutical Group
• Maruishi Pharmaceutical Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• PENN Pharmaceutical Services Ltd.
• Piramal Critical Care
• Nichi-Iko Pharmaceutical Co., Ltd.
• Sandoz Group AG
• Mylan (Viatris)
• Fresenius Kabi AG
• Troikaa Pharmaceuticals Ltd.
• Rusan Pharma Ltd.

Recent Developments

• In June 2026, Parnell announced the launch of its Sevoflurane Inhalation Anesthetic, further expanding its anesthesia portfolio to better support veterinary teams across the entire procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, this new product offers clinics a reliable, cost effective inhalant anesthetic from a company they already trust.(Source: https://www.businesswire.com)
• In February 2026, Piramal Critical Care, Inc. (PCC) and Blue-Zone Technologies Ltd. (Blue-Zone) announced a collaboration to develop full-lifecycle technology to capture and recycle waste anesthetic gases. Using Blue-Zone's technology, PCC will process captured waste anesthetic gas to produce Sevoflurane USP for human use in Canada. The partners expect the capture, collection, and recycling of waste anesthetic gas, as well as the marketing of Sevoflurane USP produced from it, to expand into additional geographies over time.(Source: https://www.eqs-news.com)

Segments Covered in the Report

By Product Type

• Branded Sevoflurane
• Generic Sevoflurane
• High-Purity Sevoflurane
• Pediatric Grade Sevoflurane
• Hospital Grade Sevoflurane

By Formulation

• Liquid Sevoflurane
• Stabilized Sevoflurane

By Application

• General Surgery
• Cardiovascular Surgery
• Orthopedic Surgery
• Neurological Surgery
• Pediatric Surgery
• Ambulatory Surgery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Academic & Research Institutes

By Distribution Channel

• Direct Tender Sales
• Hospital Pharmacies
• Pharmaceutical Distributors
• Online Procurement Platforms

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa